Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.
Abnormal adhesion of red blood cells to the endothelium and the production of cytokines and vasoactive substances, such as endothelin-1 contribute to the pathogenesis of microvascular occlusion in sickle cell disease (SCD), even during the steady state. Endothelin-3 (ET-3) is a vasoconstrictive agent, which has not yet been studied in SCD.
Makis
Alexandros C
AC
Hatzimichael
Eleftheria C
EC
Kolios
George
G
Bourantas
Konstantinos L
KL
D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood* / Q000188:drug therapy*; D000986:Antisickling Agents / Q000627:therapeutic use*; D019334:Endothelin-3 / Q000097:blood*; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D000986:Antisickling Agents; D019334:Endothelin-3; D006918:Hydroxyurea